Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions

Dur E. Nishwa; Hafiza Arooba Riaz; Muhammad Salman Tiwana; Ameer Fatima; Braira Wahid

doi:10.2217/fvl-2023-0193

Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions

Dur E. Nishwa, Hafiza Arooba Riaz, Muhammad Salman Tiwana, Ameer Fatima, Braira Wahid

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: Our study aimed to assess the response to direct-acting antiviral drugs (DAAs) among hepatitis C virus (HCV)-infected patients who also had other comorbid conditions.

Materials & methods: The data was examined based on a variety of categories, encompassing age, gender, liver function enzymes, tumor markers and comorbid conditions.

Results: In conclusion, DAAs demonstrated relatively effective results in HCV/hepatitis B virus coinfected patients, with a 78.2% sustained virological response rate, and 55.5% among HCV monoinfected patients in our study sample. However, some challenges remain, as we observed certain adverse effects associated with DAAs.

Conclusion: In the past, interferon-based treatment regimens were the primary options against HCV; however, their limited success led to the development of DAAs drugs that reportedly cause adverse outcomes occasionally.

Original language	English
Pages (from-to)	77-86
Number of pages	10
Journal	Future Virology
Volume	19
Issue number	2-4
DOIs	https://doi.org/10.2217/fvl-2023-0193
Publication status	Published - 2024
Externally published	Yes

Keywords

coinfected
DAAs
HCV
interferon
SVR

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fvl-2023-0193Licence: In Copyright

Cite this

@article{36545d76fa8a48e1b2f8b2b1b5b0abda,

title = "Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions",

abstract = "Aim: Our study aimed to assess the response to direct-acting antiviral drugs (DAAs) among hepatitis C virus (HCV)-infected patients who also had other comorbid conditions.Materials & methods: The data was examined based on a variety of categories, encompassing age, gender, liver function enzymes, tumor markers and comorbid conditions.Results: In conclusion, DAAs demonstrated relatively effective results in HCV/hepatitis B virus coinfected patients, with a 78.2% sustained virological response rate, and 55.5% among HCV monoinfected patients in our study sample. However, some challenges remain, as we observed certain adverse effects associated with DAAs.Conclusion: In the past, interferon-based treatment regimens were the primary options against HCV; however, their limited success led to the development of DAAs drugs that reportedly cause adverse outcomes occasionally.",

keywords = "coinfected, DAAs, HCV, interferon, SVR",

author = "Nishwa, {Dur E.} and Riaz, {Hafiza Arooba} and Tiwana, {Muhammad Salman} and Ameer Fatima and Braira Wahid",

year = "2024",

doi = "10.2217/fvl-2023-0193",

language = "English",

volume = "19",

pages = "77--86",

journal = "Future Virology",

issn = "1746-0794",

publisher = "Taylor & Francis",

number = "2-4",

}

TY - JOUR

T1 - Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions

AU - Nishwa, Dur E.

AU - Riaz, Hafiza Arooba

AU - Tiwana, Muhammad Salman

AU - Fatima, Ameer

AU - Wahid, Braira

PY - 2024

Y1 - 2024

N2 - Aim: Our study aimed to assess the response to direct-acting antiviral drugs (DAAs) among hepatitis C virus (HCV)-infected patients who also had other comorbid conditions.Materials & methods: The data was examined based on a variety of categories, encompassing age, gender, liver function enzymes, tumor markers and comorbid conditions.Results: In conclusion, DAAs demonstrated relatively effective results in HCV/hepatitis B virus coinfected patients, with a 78.2% sustained virological response rate, and 55.5% among HCV monoinfected patients in our study sample. However, some challenges remain, as we observed certain adverse effects associated with DAAs.Conclusion: In the past, interferon-based treatment regimens were the primary options against HCV; however, their limited success led to the development of DAAs drugs that reportedly cause adverse outcomes occasionally.

AB - Aim: Our study aimed to assess the response to direct-acting antiviral drugs (DAAs) among hepatitis C virus (HCV)-infected patients who also had other comorbid conditions.Materials & methods: The data was examined based on a variety of categories, encompassing age, gender, liver function enzymes, tumor markers and comorbid conditions.Results: In conclusion, DAAs demonstrated relatively effective results in HCV/hepatitis B virus coinfected patients, with a 78.2% sustained virological response rate, and 55.5% among HCV monoinfected patients in our study sample. However, some challenges remain, as we observed certain adverse effects associated with DAAs.Conclusion: In the past, interferon-based treatment regimens were the primary options against HCV; however, their limited success led to the development of DAAs drugs that reportedly cause adverse outcomes occasionally.

KW - coinfected

KW - DAAs

KW - HCV

KW - interferon

KW - SVR

UR - http://www.scopus.com/inward/record.url?scp=85193321881&partnerID=8YFLogxK

U2 - 10.2217/fvl-2023-0193

DO - 10.2217/fvl-2023-0193

M3 - Article

AN - SCOPUS:85193321881

SN - 1746-0794

VL - 19

SP - 77

EP - 86

JO - Future Virology

JF - Future Virology

IS - 2-4

ER -

Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this